Paroxetine Versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study

Overview

Journal Clin Psychopharmacol Neurosci

Specialty Psychiatry

Date 2017 Oct 28

PMID 29073751

Citations 2

Authors

Young Sup Woo

Roger S McIntyre

Jung-Bum Kim

Min-Soo Lee

Jae-Min Kim

Hyeon Woo Yim

Tae-Youn Jun

Affiliations

Soon will be listed here.

Abstract

Objective: The purpose of this study was to compare the efficacy and safety of escitalopram, paroxetine and venlafaxine in Korean patients with major depressive disorder (MDD).

Methods: A total of 449 Korean MDD patients were recruited in a six-week, randomized, rater-blinded, active-controlled trial and were evenly randomized to paroxetine, venlafaxine, or escitalopram treatment.

Results: When comparing the mean difference for the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Hamilton Depression Rating Scale (HDRS) total scores during six weeks, paroxetine (-6.4±0.4, and -5.4±0.4, respectively) was found to be significantly superior to escitalopram (-3.7±0.5 and -3.1±0.4, respectively). Venlafaxine had a significantly lower MADRS total score (-5.4±0.4) than escitalopram. When adjusting baseline variables, the response, according to the MADRS and HDRS scores, in the paroxetine group was greater than that for the escitalopram group (odds ratio [OR]=2.43, 95% confidence interval [CI]=1.42-4.16 for MADRS; and OR=2.32, 95% CI=1.35-3.97 for HDRS) and the venlafaxine group (OR=1.94, 95% CI=1.17-3.21 for MADRS; and OR=1.71, 95% CI=1.03-2.83 for HDRS). Despite that the overall tolerability was high and similar among the three groups, a total of 268 subjects (59.7%) prematurely discontinued treatment, representing the main limitation of the present study.

Conclusion: Although a low study completion rate limits generalizability, our findings suggest that paroxetine might be superior to escitalopram in Korean MDD patients. Further studies should be conducted to draw a definite conclusion.

Citing Articles

Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis.

Wang Z, Li H, Kang Y, Liu Y, Shan L, Wang F Ther Clin Risk Manag. 2022; 18:799-812.

PMID: 35992228 PMC: 9386738. DOI: 10.2147/TCRM.S363404.

5-HTTLPR and >T polymorphisms and response to yoga-based lifestyle intervention in major depressive disorder: A randomized active-controlled trial.

Tolahunase M, Sagar R, Dada R Indian J Psychiatry. 2018; 60(4):410-426.

PMID: 30581206 PMC: 6278208. DOI: 10.4103/psychiatry.IndianJPsychiatry_398_17.

References

Suzuki A, Aoshima T, Fukasawa T, Yoshida K, Higuchi H, Shimizu T . A three-factor model of the MADRS in major depressive disorder. Depress Anxiety. 2005; 21(2):95-7. DOI: 10.1002/da.20058. View

Trivedi M, Rush A, Wisniewski S, Nierenberg A, Warden D, Ritz L . Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006; 163(1):28-40. DOI: 10.1176/appi.ajp.163.1.28. View

Bousman C, Sarris J, Won E, Chang H, Singh A, Lee H . Escitalopram efficacy in depression: a cross-ethnicity examination of the serotonin transporter promoter polymorphism. J Clin Psychopharmacol. 2014; 34(5):645-8. DOI: 10.1097/JCP.0000000000000165. View

Yeung A, Chang D . Mood disorders in Asians. Asian J Psychiatr. 2014; 7(1):71-3. DOI: 10.1016/j.ajp.2013.11.008. View

Waza K, Graham A, Zyzanski S, Inoue K . Comparison of symptoms in Japanese and American depressed primary care patients. Fam Pract. 1999; 16(5):528-33. DOI: 10.1093/fampra/16.5.528. View

Georg Hsu L, Yu Mui Wan , Chang H, Summergrad P, Tsang B, Chen H . Stigma of depression is more severe in Chinese Americans than Caucasian Americans. Psychiatry. 2008; 71(3):210-8. DOI: 10.1521/psyc.2008.71.3.210. View

Chen P, Wang S, Poland R, Lin K . Biological variations in depression and anxiety between East and West. CNS Neurosci Ther. 2009; 15(3):283-94. PMC: 6493998. DOI: 10.1111/j.1755-5949.2009.00093.x. View

Kim D, Lim S, Lee S, Sohn S, Kim S, Hahn C . Serotonin transporter gene polymorphism and antidepressant response. Neuroreport. 2000; 11(1):215-9. DOI: 10.1097/00001756-200001170-00042. View

Serretti A, Mandelli L, Lorenzi C, Pirovano A, Olgiati P, Colombo C . Serotonin transporter gene influences the time course of improvement of "core" depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. Psychiatry Res. 2006; 149(1-3):185-93. DOI: 10.1016/j.psychres.2006.03.020. View

10.

Taylor S, Way B, Welch W, Hilmert C, Lehman B, Eisenberger N . Early family environment, current adversity, the serotonin transporter promoter polymorphism, and depressive symptomatology. Biol Psychiatry. 2006; 60(7):671-6. DOI: 10.1016/j.biopsych.2006.04.019. View

11.

Takeuchi D, Chung R, Lin K, Shen H, Kurasaki K, Chun C . Lifetime and twelve-month prevalence rates of major depressive episodes and dysthymia among Chinese Americans in Los Angeles. Am J Psychiatry. 1998; 155(10):1407-14. DOI: 10.1176/ajp.155.10.1407. View

12.

Kirchheiner J, Nickchen K, Bauer M, Wong M, Licinio J, Roots I . Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004; 9(5):442-73. DOI: 10.1038/sj.mp.4001494. View

13.

Yoshimura R, Umene-Nakano W, Suzuki A, Ueda N, Miyamoto K, Ikenouchi-Sugita A . Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Hum Psychopharmacol. 2009; 24(6):489-94. DOI: 10.1002/hup.1043. View

14.

Won E, Park S, Han K, Sung S, Lee H, Paik J . Evidence-based, pharmacological treatment guideline for depression in Korea, revised edition. J Korean Med Sci. 2014; 29(4):468-84. PMC: 3991789. DOI: 10.3346/jkms.2014.29.4.468. View

15.

DEmpaire I, Guico-Pabia C, Preskorn S . Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant?. J Psychiatr Pract. 2011; 17(5):330-9. DOI: 10.1097/01.pra.0000405363.95881.01. View

16.

Weissman M, Bland R, Canino G, Faravelli C, Greenwald S, Hwu H . Cross-national epidemiology of major depression and bipolar disorder. JAMA. 1996; 276(4):293-9. View

17.

Seo J, Song H, Bin Lee H, Park Y, Hong J, Kim W . The Korean Medication Algorithm for Depressive Disorder: second revision. J Affect Disord. 2014; 167:312-21. DOI: 10.1016/j.jad.2014.05.031. View

18.

Hansen R, Moore C, Dusetzina S, Leinwand B, Gartlehner G, Gaynes B . Controlling for drug dose in systematic review and meta-analysis: a case study of the effect of antidepressant dose. Med Decis Making. 2009; 29(1):91-103. PMC: 2657322. DOI: 10.1177/0272989X08323298. View

19.

Cipriani A, Furukawa T, Salanti G, Geddes J, Higgins J, Churchill R . Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 373(9665):746-58. DOI: 10.1016/S0140-6736(09)60046-5. View

20.

Higuchi T . Major depressive disorder treatment guidelines in Japan. J Clin Psychiatry. 2010; 71 Suppl E1:e05. DOI: 10.4088/JCP.9058se1c.05gry. View